Paper: Real-World Outcomes with Fedratinib Therapy in Patients Who Discontinued Ruxolitinib for Primary Myelofibrosis
Real-world Outcomes of Fedratinib in Patients with Myelofibrosis who Discontinued Ruxolitinib
Real-world Outcomes of Fedratinib in Patients with Myelofibrosis who Discontinued Ruxolitinib
Read the full article here
Read the full article here
Read the full article here
Keywords: vertical jumps, testing, ACL, return to sport Vertical jumps play a crucial role in the return-to-sport testing protocol following anterior cruciate ligament reconstruction (ACLR).…
Plans by the prime minister, Rishi Sunak, to overhaul the sick note system in the UK have left me with mixed emotions. A more independent…
Walsh and colleagues call for prudence in their editorial on lecanemab for Alzheimer’s disease. This call should be extended to dementia and Alzheimer’s disease research…
ERS is an international membership organisation that unites physicians, health professionals, scientists and other experts working in respiratory medicine.
New research has found that every pound saved in closing police stations costs the rest of us £3
Objective To determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of…
Metal-ion-dependent nucleases play crucial roles in cellular defense and biotechnological applications. Time-resolved crystallography has resolved catalytic details of metal-ion-dependent DNA hydrolysis and synthesis, uncovering the…